Apic Bio, Inc., an American gene therapy company for treatment of rare genetic diseases, has raised US$40 million, led by Chinese early-stage venture capital group Morningside Venture Investments, according to a January 7 announcement.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?